From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

Bibliography

• Barlogie B, Shaughnessy J, Tricot G, Treatment of multiple myeloma. Blood 2004;103(1):20-32
   PubMed Web of Science ®Google Scholar
• Tsuchiya J, Murakami H, Kanoh T, Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol 1994;87(4):832-4
   PubMed Web of Science ®Google Scholar
• Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33(2):86-9
   PubMed Web of Science ®Google Scholar
• Riccardi A, Mora O, Tinelli C, Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000;82(7):1254-60
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335(2):91-7
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Podar K, Richardson PG, Hideshima T, The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007;20(4):597-612
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24(3):431-6
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Rosinol L, Hussein M, Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26(13):2171-7
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM, Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112(8):3107-14
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Lokhorst HM, Dimopoulos M, Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2010;37(4):266-83
   PubMed Web of Science ®Google Scholar
• Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Rev 2010;24(3):91-100
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24(Suppl 1):S5-11
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104(3):607-18
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Hideshima T, Chauhan D, Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009;46(2):166-75
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Zhu YX, Schmidt J, Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010;115(8):1594-604
   PubMed Web of Science ®Google Scholar
• Wang X, Sinn AL, Pollok K, Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 2010;150(3):313-25
   PubMed Web of Science ®Google Scholar
• Fletcher GC, Brokx RD, Denny TA, ENMD-2076 Is an orally-active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10(1):126-37
   Google Scholar
• Diamond JR, Bastos BR, Hansen RJ, Phase I safety, pharmacokinetic and pharmacodynamic study of enmd-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17(4):849-60
   Google Scholar
• Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16(11):2989-98
   PubMed Web of Science ®Google Scholar
• Kumar S, Gertz MA, Dispenzieri A, Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78(1):34-9
   PubMed Web of Science ®Google Scholar
• Chauhan D, Uchiyama H, Akbarali Y, Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87(3):1104-12
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazelhurst LA, Cell adhesion mediated drug-resistance (CAM-DR): role of integrins and resistance to apoptosis in human cell lines. Blood 1999;93:1658-67
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950-61
   PubMed Web of Science ®Google Scholar
• Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005;18(4):509-24
   PubMed Web of Science ®Google Scholar
• Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84(6):2008-11
   PubMed Web of Science ®Google Scholar
• Ludwig H, Nachbaur DM, Fritz E, Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77(12):2794-5
   PubMed Web of Science ®Google Scholar
• Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91(1):3-21
   PubMed Web of Science ®Google Scholar
• Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 1999;13(6):1145-57
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Muller-Newen G, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314
   PubMedGoogle Scholar
• Ogata A, Chauhan D, Teoh G, IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159(5):2212-21
   PubMed Web of Science ®Google Scholar
• Billadeau D, Jelinek DF, Shah N, Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995;55(16):3640-6
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10(1):105-15
   PubMed Web of Science ®Google Scholar
• Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29(12):3945-50
   PubMed Web of Science ®Google Scholar
• Choi Y, Zhang J, Murga C, PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002;21(34):5289-300
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100(1):194-9
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96(6):857-68
   PubMed Web of Science ®Google Scholar
• Vanderkerken K, Asosingh K, Braet F, Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93(1):235-41
   PubMed Web of Science ®Google Scholar
• Agrawal NR, Bukowski RM, Rybicki LA, A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 2003;98(1):94-9
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-47
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ, Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221-30
   PubMed Web of Science ®Google Scholar
• Ogawa M, Nishiura T, Oritani K, Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60(15):4262-9
   PubMed Web of Science ®Google Scholar
• Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002;99(11):4138-46
   PubMed Web of Science ®Google Scholar
• Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64(20):7183-90
   PubMed Web of Science ®Google Scholar
• Podar K, Catley LP, Tai YT, GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004;103(9):3474-9
   PubMed Web of Science ®Google Scholar
• Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99(7):2532-40
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Podar K, Amiot M, VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004;104(9):2886-92
   PubMed Web of Science ®Google Scholar
• Bisping G, Leo R, Wenning D, Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101(7):2775-83
   PubMed Web of Science ®Google Scholar
• Chesi M, Brents LA, Ely SA, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-36
   PubMed Web of Science ®Google Scholar
• Otsuki T, Yamada O, Yata K, Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation. Int J Oncol 1999;15(6):1205-12
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA, Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16(3):260-4
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Garban F, Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21(9):2020-4
   PubMed Web of Science ®Google Scholar
• Chng WJ, Braggio E, Mulligan G, The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008;111(3):1603-9
   PubMed Web of Science ®Google Scholar
• Kanai M, Goke M, Tsunekawa S, Podolsky DK. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem 1997;272(10):6621-8
   PubMed Web of Science ®Google Scholar
• Hart KC, Robertson SC, Kanemitsu MY, Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19(29):3309-20
   PubMed Web of Science ®Google Scholar
• Plowright EE, Li Z, Bergsagel PL, Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95(3):992-8
   PubMed Web of Science ®Google Scholar
• Paterson JL, Li Z, Wen XY, Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004;124(5):595-603
   PubMed Web of Science ®Google Scholar
• Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15(6):672-83
   PubMed Web of Science ®Google Scholar
• Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22(4):451-64
   PubMedGoogle Scholar
• Gautschi O, Heighway J, Mack PC, Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14(6):1639-48
   PubMed Web of Science ®Google Scholar
• Hirota T, Kunitoku N, Sasayama T, Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114(5):585-98
   PubMed Web of Science ®Google Scholar
• Cazales M, Schmitt E, Montembault E, CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle 2005;4(9):1233-8
   PubMed Web of Science ®Google Scholar
• Lens SM, Rodriguez JA, Vader G, Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 2006;17(4):1897-909
   PubMed Web of Science ®Google Scholar
• Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008;34(2):175-82
   PubMed Web of Science ®Google Scholar
• Manfredi MG, Ecsedy JA, Meetze KA, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora a kinase. Proc Natl Acad Sci USA 2007;104(10):4106-11
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64(4):1546-58
   PubMedGoogle Scholar
• Hose D, Reme T, Meissner T, Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113(18):4331-40
   PubMed Web of Science ®Google Scholar
• Bray MR, Fletcher GC, Denny TA, ENMD-981693 is an orally-active kinase inhibitor with activity towards human hematologic cancers in vitro and in vivo. Blood 2006;108: Abstract 1377
   Google Scholar
• Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281(5381):1322-6
   PubMed Web of Science ®Google Scholar
• Puthier D, Pellat-Deceunynck C, Barille S, Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13(2):289-94
   PubMed Web of Science ®Google Scholar
• Miguel-Garcia A, Orero T, Matutes E, Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 1998;83(4):298-304
   PubMedGoogle Scholar
• Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996;13(7):1511-19
   PubMed Web of Science ®Google Scholar
• Huang DC, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. Embo J 1997;16(15):4628-38
   PubMed Web of Science ®Google Scholar
• Tu Y, Renner S, Xu F, BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58(2):256-62
   PubMed Web of Science ®Google Scholar
• Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002;8(11):3527-38
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004;34(11):3156-64
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V, Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21(37):5673-83
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Abe S, Kurata M, IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81(11):824-31
   PubMed Web of Science ®Google Scholar
• Romagnoli M, Trichet V, David C, Significant impact of survivin on myeloma cell growth. Leukemia 2007;21(5):1070-8
   PubMed Web of Science ®Google Scholar
• Younes H, Leleu X, Hatjiharissi E, Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007;13(13):3771-5
   PubMed Web of Science ®Google Scholar
• Schultz WA. Molcular Biology of Human Cancers. Norwell, MA: Springer, 2005
   Google Scholar
• Letai A. Growth factor withdrawal and apoptosis: the middle game. Mol Cell 2006;21(6):728-30
   PubMed Web of Science ®Google Scholar
• Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000;10(1):47-50
   PubMed Web of Science ®Google Scholar
• Hauf S, Cole RW, LaTerra S, The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161(2):281-94
   PubMed Web of Science ®Google Scholar
• Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14(8):3325-41
   PubMed Web of Science ®Google Scholar
• Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14(1):29-36
   PubMed Web of Science ®Google Scholar
• Hembrough TA, Chen X, Burke PA, Inhibition of multiple myeloma tumor growth and FGFR3 by the aurora-angiogenesis inhibitor ENMD-981693. Blood (ASH Annual Meeting Abstracts) 2007;110: Abstract 1209
   Google Scholar
• Farag SS, Zhang S, Suvannasankha A, Clinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma: Interim Phase I Trial Results 52nd ASH Annual Metting and Exposition; 2010; Orlando, FL; 2010. p. Abstract 1957
   Google Scholar
• Yee KW, Brandwein J, MInden MD, A Phase I study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML). Mol Cancer Ther 2009;8(12 Suppl):A106
   Google Scholar
• Evans R, Naber C, Steffler T, Aurora a kinase RNAi and small molecule inhibition of aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008;49(3):559-69
   PubMed Web of Science ®Google Scholar
• Evans RP, Naber C, Steffler T, The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140(3):295-302
   PubMed Web of Science ®Google Scholar
• Santo L, Hideshima T, Cirstea D, Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res 2011. [Epub ahead of print]
   Google Scholar
• Negri JM, McMillin DW, Delmore J, In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009;147(5):672-6
   PubMed Web of Science ®Google Scholar
• Gorgun G, Calabrese E, Hideshima T, A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115(25):5202-13
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Reece DE, Marcellus D, A Phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145. Invest New Drugs 2006;24(6):529-35
   PubMed Web of Science ®Google Scholar
• Prince HM, Honemann D, Spencer A, Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a Phase II study of pazopanib (GW786034). Blood 2009;113(19):4819-20
   PubMed Web of Science ®Google Scholar
• Zangari M, Anaissie E, Stopeck A, Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004;10(1 Pt 1):88-95
   PubMed Web of Science ®Google Scholar
• Farag SS, Zhang S, Jansak BS, Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2009;33:1475-80
   Google Scholar
• Wang X, Sinn AL, Suvannasankha A, The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in vitro and in vivo, and Shows Synergistic Activity in Combination with Lenalidomide. Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 3660
   Google Scholar
• Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845-52
   PubMed Web of Science ®Google Scholar